Fatemeh Mirzayeh Fashami

Ms. Fatemeh Mirzayeh Fashami

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2024 in Value in Health
Verified
Journal Article
Open access
STShiro Tanaka
Shiro Tanaka
AIAtaru Igarashi
Ataru Igarashi
RMRaf De Moor
Raf De Moor
NLNan Li
Nan Li
MHMariko Hirozane
Mariko Hirozane
CCChris Cameron
Chris Cameron
Controls and governance over the methodology and reporting of indirect treatment comparisons (ITCs) have been introduced to minimize bias and ensure scientific credibility and transparency in healthcare decision-making. The objective of this study was to highlight ITC techniques that are key to conducting objective and analytically-sound analyses, and to ascertain circumstantial suitability of ITCs as a source of comparative evidence for healthcare interventions. Ovid MEDLINE® was searched from January 2010 through August 2023 to identify publicly available ITC-related documents (i.e., guidelines and best practices) in the English language. This was supplemented with hand-searches of websites of various international organizations, regulatory agencies, and reimbursement agencies of Europe, North America, and Asia-Pacific. The jurisdiction-specific ITC methodology and reporting recommendations were reviewed. Sixty-eight guidelines from 10 authorities worldwide were included for synthesis. Many of the included guidelines were updated within the last five years and commonly cited the absence of direct comparative studies as primary justification for employing ITCs. Most jurisdictions favored population-adjusted or anchored ITC techniques opposed to naïve comparisons. Recommendations on the reporting and presentation of these ITCs varied across authorities; however, there was some overlap among the key elements. Given the challenges of conducting head-to-head randomized controlled trials, comparative data from ITCs offer valuable insights into clinical effectiveness. As such, multiple ITC guidelines have emerged worldwide. According to the most recent versions of the guidelines, the suitability and subsequent acceptability of the ITC technique employed depends on the data sources, available evidence, and magnitude of benefit/uncertainty.

20 September 2024 in International Journal of Mental Health and Addiction
Verified
Journal Article
Open access
PDF file
MKMalahat Khalili
Malahat Khalili
Behnam SadeghiradBehnam Sadeghirad
Behnam Sadeghirad
PBPaxton Bach
Paxton Bach
ACAlexis Crabtree
Alexis Crabtree
SJSara Javadi
Sara Javadi
MKMohammad Karamouzian
Mohammad Karamouzian
The current evidence regarding effective management of methamphetamine and amphetamine (MA/A) use disorders is inconclusive. Therefore, we assessed the comparative benefits and tolerability of pharmacological, psychosocial, and harm reduction interventions for management of MA/A use disorders. We searched six electronic databases for randomized controlled trials of any pharmacological, psychosocial, or harm reduction interventions in adults with MA/A use disorders. We performed a random-effects frequentist network meta-analysis and used the GRADE approach to assess the certainty of evidence. We included 72 randomized trials (6836 participants). Low certainty evidence suggests quetiapine may extend abstinence compared to placebo [risk ratio (RR) 3.17 (95% confidence intervals (CI), 1.24 to 8.07)] and weekly average proportion of patients with negative urine samples [mean difference (MD) 32.17 (95% CI, 14.08 to 50.26)]. Low certainty evidence also suggested that riluzole may be associated with a higher weekly average proportion of patients with negative urine samples [MD 24.10 (95% CI, 5.54 to 42.66)]. Very low certainty evidence suggests methylphenidate alone [compared to placebo MD 10.24 (95% CI, 3.49 to 16.99)] or in combination with matrix model [MD 23.55 (95% CI, 7.64 to 39.46)] may be associated with an increased weekly average proportion of patients with negative urine samples. Compared to placebo, contingency management alone [MD 21.20 (95% CI, 11.39 to 31.00), very low certainty] or in combination with cognitive behavioural therapy [MD 34.85 (95% CI, 19.63 to 50.08), very low certainty] may be associated with longer duration of abstinence. Compared to placebo, venlafaxine [RR 0.27 (95% CI 0.08 to 0.90), low certainty] and citicoline [RR 0.69 (95% CI 0.49 to 0.99), lowcertainty] may be among the most tolerable interventions. Very few interventions may be associated with slight improvement in certain outcomes, but no intervention showed moderate- to high-certainty evidence for important changes across any patient-important outcomes.

5 August 2024 in PharmacoEconomics - Open
Verified
Journal Article
Open access
PDF file
FFFatemeh Mirzayeh Fashami
Fatemeh Mirzayeh Fashami
JTJean Éric Tarride
Jean Éric Tarride
Behnam SadeghiradBehnam Sadeghirad
Behnam Sadeghirad
KHKimia Hariri
Kimia Hariri
APAmirreza Peyrovinasab
Amirreza Peyrovinasab
MLMitchell A. H. Levine
Mitchell A. H. Levine
Introduction Identifying key differences between manufacturers’ submitted analysis and economic reanalysis by the Canadian Agency for Drugs and Technologies in Health (CADTH) is an important step toward understanding reimbursement recommendations. We compared economic values reported in manufacturers’ analysis with the CADTH reanalysis and also assessed methodological critiques. Methods Two reviewers extracted data from the clinical and economic reports in publicly available CADTH reports from 2018 to 2022. We used the Wilcoxon rank-sum test to assess the difference between mean economic values, and the Chi-square test to assess the association between the CADTH critique final recommendations. Results Of the total submissions, 99.4% included effectiveness critiques, 88.8% included model structure critiques, 69.1% included utility score critiques, and 78.7% included cost critiques. The median incremental cost-utility ratio (ICUR) in the manufacturers’ analyses was $138,658/quality-adjusted life-year (QALY), 2.5-fold lower than the CADTH’s reanalysis at $380,251/QALY (p < 0.001). The median CADTH reanalysis for 3-year budget impact analysis (BIA) was $4,575,102, which was 27% higher than the manufacturers’ submitted 3-year BIA (p < 0.001). CADTH requested a price reduction for 95% of all submissions, and the median price reduction request was 63.5%. In 2021 and 2022, the willingness-to-pay threshold identified in CADTH reports remained constant at $50,000 per QALY gained for all medications. Conclusion There was high frequency of CADTH critiques on manufacturers’ submissions in all four aspects of economic submissions: effectiveness, cost, utility score and structure. We observed a higher median incremental cost and lower median incremental QALYs in the CADTH reanalysis compared with the manufacturers’ submissions. The resulting higher ICUR in the CADTH reanalysis often leads to a recommendation that the manufacturer needs to reduce its price. The 3-year budget impact was higher in the CADTH reanalyses compared with manufacturers’ submissions.

1 June 2026 in Annals of Internal Medicine
Verified
Journal Article
Closed access
MKMalahat Khalili
Malahat Khalili
Faraidoon HaghdoostFaraidoon Haghdoost
Faraidoon Haghdoost
ALAmin Liaghatdar
Amin Liaghatdar
KTKian Torabiardakani
Kian Torabiardakani
FMFatemeh Mahdian
Fatemeh Mahdian
Behnam SadeghiradBehnam Sadeghirad
Behnam Sadeghirad
Chronic migraine headaches occur on 15 or more days per month and affect quality of life. This systematic review and meta-analysis summarizes the evidence for effectiveness and tolerability of phar... Background: Migraine headaches are considered chronic when they occur on 15 or more days per month. Newer medications are available for prevention. Purpose: To explore the effectiveness and tolerab...

2 May 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
FFFatemeh Mirzayeh Fashami
Fatemeh Mirzayeh Fashami
MLMitchell A. H. Levine
Mitchell A. H. Levine
FXFeng Xie
Feng Xie
GBGordon Blackhouse
Gordon Blackhouse
JTJean Éric Tarride
Jean Éric Tarride
Pancreatic cancer has an annual incidence of 2/10,000 in Canada, with a one-year mortality rate greater than 80%. In the absence of a cost-effectiveness analysis in Canada, this study’s objective was to assess the cost-effectiveness of olaparib versus a placebo in adult patients with deleterious or suspected deleterious BRCA metastatic pancreatic adenocarcinoma, who did not show any progression for at least 16 weeks with first-line platinum-based chemotherapy. A partitioned survival model with a 5-year time horizon was adopted to estimate the costs and effectiveness. All of the costs were extracted from the public payer’s available resources, effectiveness data were obtained from the POLO trial, and Canadian studies were used for utility inputs. Probabilistic sensitivity analyses and scenario analyses were performed. The total costs of olaparib and the placebo over five years were CAD 179,477 and CAD 68,569, with overall quality-adjusted life-years (QALYs) of 1.70 and 1.36, respectively. The incremental cost-effectiveness ratio (ICER) of the olaparib group compared with the placebo was CAD 329,517 per QALY. With a commonly cited willingness to pay (WTP) threshold of CAD 50,000 per QALY, the drug does not achieve acceptable cost-effectiveness mainly due to the high price of the medication and insufficient impact on the overall survival of patients with metastatic pancreatic cancer.

14 April 2026 in PharmacoEconomics - Open
Verified
Journal Article
Open access
JFJeanine Flanigan
Jeanine Flanigan
SKSarah Kane
Sarah Kane
FFFatemeh Mirzayeh Fashami
Fatemeh Mirzayeh Fashami
AZAnna Zhou
Anna Zhou
LALamees Almuallem
Lamees Almuallem
GLGary H. Lyman
Gary H. Lyman
Postmenopausal osteoporosis (PMO) is a major public health and economic burden in the USA. The objective of this study was to evaluate the cost-effectiveness of biosimilar denosumab compared with alendronate, risedronate, ibandronate, and zoledronic acid in treating women with PMO at high risk of fracture from a US payer perspective. A cost-effectiveness analysis was conducted using a Markov cohort model and a lifetime horizon was applied to capture long-term costs and effects. Treatment effects were based on published network meta-analyses. The cost of biosimilar denosumab was estimated on the basis of assumptions; other costs were obtained from publicly available sources. Main outcomes included quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). Biosimilar denosumab was associated with greater efficacy and higher costs versus all comparators. Over a lifetime horizon, the ICER was $101,017, $93,544, $100,515, and $144,995 per QALY gained for biosimilar denosumab compared with alendronate, risedronate, ibandronate, and zoledronic acid, respectively. Cost-effectiveness was most sensitive to starting age, discount rate, treatment duration, and biosimilar price. At a willingness-to-pay (WTP) threshold of $150,000 per QALY gained, biosimilar denosumab was likely to be cost-effective compared with alendronate, risedronate, ibandronate, and zoledronic acid in the treatment of PMO. At a WTP threshold of $100,000 per QALY gained, biosimilar denosumab was likely to be cost-effective relative to risedronate, while ICERs relative to alendronate and ibandronate only marginally exceeded this WTP threshold. Biosimilar denosumab was estimated to be cost-effective compared with alendronate, risedronate, ibandronate, and zoledronic acid at a WTP threshold of $150,000/QALY gained and compared with risedronate at a threshold of $100,000/QALY gained. As a lower-cost alternative to reference denosumab, biosimilar denosumab may enhance patient access to effective PMO treatment in the USA.